Aytu BioPharmaAYTU +0.92%40 Days Payable is 260.49 as of Mar. 2026, which is 9% below its 10-year median of 286.39. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.84 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Aytu BioPharma ranks better than 87.61% on this metric.
The historical rank and industry rank for Aytu BioPharma's Days Payable or its related term are showing as below:
AYTU'
s Days Payable Range Over the Past 10 Years
Min: 109.52 Med: 286.39 Max: 670.88
Current: 228.7
During the past 13 years, Aytu BioPharma's highest Days Payable was 670.88. The lowest was 109.52. And the median was 286.39.
AYTU's Days Payable is ranked better than 87.61% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs AYTU: 228.70
Aytu BioPharma's Days Payable
increased
from Mar. 2025 (191.84) to Mar. 2026 (260.49).
It may suggest that Aytu BioPharmadelayed paying its suppliers.
Aytu BioPharma Days Payable Related Terms
Aytu BioPharma Days Payable Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aytu BioPharma's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (AYTU) has a Days Payable of 260.49 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aytu BioPharma and its competitors. This is near median its historical median of 286.39. Over the past decade, Aytu BioPharma's Days Payable has ranged from 109.52 to 670.88. According to the industry distribution chart, Aytu BioPharma ranks #114 out of 920 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is Aytu BioPharma's Days Payable too high?
Aytu BioPharma's current Days Payable of 260.49 is near median its 10-year median of 286.39. Over the past 10 years, this metric has ranged from a low of 109.52 to a high of 670.88. The Drug Manufacturers industry median Days Payable is 90.84. Aytu BioPharma's value of 260.49 is 186.8% above this industry median. Based on the distribution chart, Aytu BioPharma ranks #114 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Days Payable compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #114 out of 920 companies for Days Payable. This places Aytu BioPharma in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Aytu BioPharma's value of 260.49 is 186.8% above this benchmark. Historically, Aytu BioPharma's own Days Payable has ranged from 109.52 to 670.88 over the past decade. While the company's 10-year median is 286.39 vs. the industry median of 90.84, Aytu BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current Days Payable of 260.49 is 186.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current Days Payable is 260.49, which is near median its own 10-year median of 286.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.84, compared to a current price of $2.19 — trading 160.7% above its estimated fair value. The current Days Payable is 260.49, which is near median its 10-year median of 286.39 and 186.8% above the Drug Manufacturers industry median of 90.84. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Days Payable is 260.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.19 is trading 160.7% above its estimated GF Value™ of $0.84.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
Days Payable: 260.49 (near median its 10-year median of 286.39)
GF Value™: $0.84 vs. price of $2.19 (160.7% above fair value)
Industry Position: 186.8% above the Drug Manufacturers median (#114 of 920)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score
Get the complete analysis for AYTU
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
